The View From ePharma Summit: Practicing What Was Being Preached!
This article is a compilation of summaries of presentations made at the 2009 ePharma Summit. Included are highlights posted to the ePharma Summit and other blogs during the conference and insights on epharma marketing issues provided by several conference speakers and attendees.
Building the Optimal Service Model: Creating the Right Physician Experiences to Drive Business
This article presents a summary of a recent TNS Healthcare webinar and personal conversations with presenters conducted beforehand. Included are NEW research results about how US and European physicians rate pharmaceutical companies against a number of customer value points that are important in achieving success with the new sales model.
The Future of DTC Advertising
Experts don't know if it's the economy, lack of new drugs in pharma's pipeline, or the new pro-regulation political climate, but 2009 is shaping up to be the year that direct-to-consumer (DTC) advertising will suffer a round of budget cuts and setbacks not seen in a long time. We poll readers and experts to help predict the immediate future of DTC advertising and to get some insights from experts.
The ePharma Pioneer Club™
Pharma Marketing Network's ePharma Pioneer Club is an EXCLUSIVE, members-only Facebook Group through which pharmaceutical eMarketing experts 'meet' to discuss and exchange views on how to advance the use of the Internet and other technologies in pharmaceutical marketing, sales, and communications.
FDA Finalizes Guidance on Distribution of Reprints
The FDA recently finalized its Good Reprint Practices for the Distribution of Medical Journal Articles. This article outlines the major provisions of the guidance and helps you learn how to make it work for your company.
The Hypocrisy of Healthcare Marketing Restrictions
Pharmaceutical marketing, some say, has benefited by the recent dramatic drop off of enforcement of domestic laws. Under a Democratic administration, they say, there will be a new emphasis on enforcement of current regulations as well as new regulations. The drug industry's response has been to increase self-regulation, but Dmitriy Kruglyak of Trusted.MD Network thinks this is cave in to hypocritical attacks by the media and other critics of the industry.